Comparison · GLP-1
Wegovy vs Zepbound · Which GLP-1 Is Right for You?
A physician-written comparison of the two leading branded weight-loss injections · what is actually different, what is the same, and how to decide.
Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are the two FDA-approved injectable medications most often prescribed for chronic weight management in adults with obesity or overweight plus a weight-related condition. Both are once-weekly subcutaneous injections, both come in pre-filled pens, and both work by mimicking gut hormones that regulate appetite and blood sugar. The clinical question almost every patient asks is the same · which one will help me lose more weight, with fewer side effects, at a price I can sustain.
The honest answer is that they are close cousins, not interchangeable. Zepbound activates two receptors (GLP-1 and GIP), while Wegovy activates one (GLP-1). In head-to-head and indirect comparisons, Zepbound has produced a larger average percent weight loss at its highest doses, but Wegovy has the longer real-world safety record and a slightly different side-effect profile. The right choice usually comes down to how your insurance covers them, how your body tolerates titration, and what your goal is.
Below is a side-by-side breakdown plus the clinical context most marketing pages skip · who each medication was studied in, how the dose ladder actually works in practice, what to expect in months one through six, and the cash and insured pricing landscape as of 2026.
Wegovy vs Zepbound · at a glance
| Wegovy (semaglutide 2.4 mg) | Zepbound (tirzepatide) | |
|---|---|---|
| Manufacturer | Novo Nordisk | Eli Lilly |
| Active ingredient | Semaglutide | Tirzepatide |
| Receptors targeted | GLP-1 | GLP-1 and GIP |
| FDA approved for weight loss | Yes (2021) | Yes (2023) |
| Dosing | Once weekly subcutaneous | Once weekly subcutaneous |
| Maintenance dose | 2.4 mg | 5, 10, or 15 mg |
| Average weight loss at 68 weeks | About 15 percent of body weight in trials | About 18 to 21 percent at higher doses in trials |
| Most common side effects | Nausea, constipation, fatigue, reflux | Nausea, diarrhea, constipation, decreased appetite |
| List price (cash, monthly) | About 1,350 USD | About 1,060 to 1,290 USD |
| Manufacturer savings card | Available for commercially insured patients | Available for commercially insured patients |
How they actually work in the body
Both medications belong to a class called incretin mimetics. Incretins are hormones released by the gut after a meal that tell the pancreas to release insulin, slow down gastric emptying, and signal the brain that you are full. Wegovy is a single-agonist · it binds the GLP-1 receptor only. Zepbound is a dual-agonist · it binds both the GLP-1 and the GIP receptor. GIP appears to add a second appetite-suppressing pathway and may also influence how fat tissue stores and burns energy.
In plain English, both drugs do three things at once. They quiet food noise. They slow how quickly the stomach empties, so you feel full longer after a normal portion. And they smooth out blood sugar swings, which reduces the energy crashes that drive late-afternoon snacking. Patients usually describe the experience as feeling neutral about food rather than constantly negotiating with it. That subjective shift, more than willpower, is what produces the weight loss the trials measured.
The dual mechanism in Zepbound is the leading hypothesis for why its average weight loss is higher in clinical trials. It is not a guarantee of more weight loss for any individual patient. Genetics, baseline insulin resistance, sleep quality, and how strict you are with the dietary changes the medication makes possible all matter at least as much as which molecule you inject.
Average weight loss · what the trials actually showed
In the STEP 1 trial, adults on Wegovy 2.4 mg for 68 weeks lost an average of 14.9 percent of their starting body weight, compared with 2.4 percent for placebo. About one in three participants lost 20 percent or more.
In SURMOUNT-1, adults on Zepbound for 72 weeks lost an average of 15 percent on the 5 mg dose, 19.5 percent on 10 mg, and 20.9 percent on 15 mg. About 36 percent of participants on the highest dose lost 25 percent or more.
There is no large head-to-head trial in the weight-management indication yet, so any direct comparison is an apples-to-pears estimate. The SURPASS-2 trial in type 2 diabetes did pit tirzepatide against semaglutide directly · tirzepatide produced more A1c reduction and more weight loss at every dose level. Most clinicians extrapolate from that signal when counseling patients, but it is worth saying out loud that your trajectory may not match the trial average in either direction.
Side effects, titration, and tolerability
Side-effect profiles are similar enough that the day-to-day experience overlaps heavily. Both medications start at a low dose and step up every four weeks. The first two weeks of any new dose are when nausea, fullness, and reflux peak. Most patients describe weeks one and two as a bigger adjustment than the rest of the month.
Wegovy is more often associated with constipation and a flatter, longer-tailed nausea pattern. Zepbound is more often associated with diarrhea early in titration, especially at the 10 mg and 15 mg steps. Both can produce gallbladder symptoms in a small subset of patients and both carry a boxed warning about thyroid C-cell tumors based on rodent studies, so neither is appropriate for patients with a personal or family history of medullary thyroid carcinoma or MEN 2.
The most controllable lever is titration speed. Slower steps almost always mean fewer side effects. If a dose increase produces severe nausea, the standard physician response is to hold at the previous dose for an extra month rather than push through · the goal is the lowest dose that maintains weight loss, not the highest dose on the label.
Cost, insurance, and the savings card landscape
Cash list price for both medications sits in the four-figure range per month, which is why coverage is the single largest predictor of which one a patient ends up on. Wegovy and Zepbound are both covered by some commercial plans, almost no Medicare plans for weight loss specifically, and a growing but still limited number of state Medicaid programs.
If your plan covers either medication, expect prior authorization that asks for a documented BMI threshold, a comorbidity such as hypertension or sleep apnea, and proof of a prior lifestyle attempt. Both manufacturers offer savings cards that can lower commercial copays, but the cards do not stack with government insurance.
If your plan does not cover either, the realistic monthly cash cost for branded Wegovy or Zepbound is well over 1,000 USD. Many patients in that situation choose physician-supervised compounded semaglutide or compounded tirzepatide as a lower-cost alternative. Compounded versions are not FDA-approved finished products, but they can be legally prescribed by a licensed clinician and dispensed by an FDA-registered 503A or 503B compounding pharmacy when there is a clinical reason. We compare the trade-offs in our compounded vs branded GLP-1 guide.
Who tends to do better on which
If you have struggled with appetite regulation for years, have a high BMI, and your insurance covers either drug, the trial data favor Zepbound for raw percent weight loss. If you have a sensitive GI system, a history of gallbladder issues, or you respond well to lower doses of medications generally, the longer real-world Wegovy track record and slightly gentler titration make it a reasonable first choice.
Patients with type 2 diabetes have a fourth consideration · semaglutide is also marketed as Ozempic and tirzepatide as Mounjaro for diabetes. The same molecule, different label. If diabetes coverage is easier to secure than obesity coverage on your plan, that may dictate the choice for you.
The honest physician answer is that the best GLP-1 is the one you can actually access, tolerate, and stay on for at least a year. Stopping either medication usually leads to weight regain within twelve months · the trials that followed patients off-drug consistently showed two-thirds of the lost weight returning. Long-term success is a long-term plan.
Frequently asked questions
Is Zepbound stronger than Wegovy?
On average yes · in separate trials Zepbound at its 15 mg dose produced about 21 percent body-weight loss versus about 15 percent for Wegovy at 2.4 mg. There is no published head-to-head obesity trial, and individual response varies. Some patients lose more on Wegovy than they would on Zepbound.
Can I switch from Wegovy to Zepbound?
Yes, with physician supervision. The standard approach is to stop Wegovy, wait one week, and start Zepbound at 2.5 mg with a normal four-week titration. Switching does not reset your weight loss · most patients pick up the trajectory they were on.
Are Wegovy and Zepbound covered by insurance?
Coverage varies by plan and is the single biggest factor in monthly cost. Commercial plans increasingly cover one or both with prior authorization. Medicare does not cover either for weight loss as of 2026. We will run a free benefits check before you start.
How long do I have to stay on it?
Obesity medicine guidelines treat GLP-1s as long-term therapy, the same way blood pressure medication is. Trials that withdrew the medication after a year showed about two-thirds of the weight returning within twelve months. A maintenance dose long-term is the most common plan.
Not sure which one is right for you?
Take the two-minute quiz · Dr. Linda will recommend a starting medication based on your weight goals, insurance, and tolerance for side effects. No charge to find out.
This page is educational and is not a substitute for medical advice. Wegovy and Zepbound are prescription medications. Eligibility, dosing, and pricing are determined after a clinical evaluation by a licensed physician.